Vischer: Anokion raises $35 million financing

Anokion, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. Founded in Switzerland and based on innovation from the EPFL Life Sciences, Anokion is led by a diverse team of entrepreneurial scientists and experienced industry professionals, striving to transform treatment for autoimmune patients around the world.

VISCHER acted as legal advisor to Anokion in this transaction. The team included partner Matthias Staehelin (pictured), Vincent Reardon and Luzius Zumstein (all corporate/m&a).